What Banner Life Sciences does

Banner Life Sciences is a privately held specialty pharmaceutical company headquartered in High Point, North Carolina, that develops and commercializes therapeutics for patients with unmet clinical needs. Its sole commercial product is BAFIERTAM (monomethyl fumarate) delayed-release capsules, an oral disease-modifying therapy approved by the FDA on April 30, 2020 for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BAFIERTAM was developed under the FDA's 505(b)(2) pathway and is positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate), leveraging proprietary formulation technology that delivers monomethyl fumarate directly without requiring metabolic conversion and supports claims of no dietary restrictions and potentially improved gastrointestinal tolerability versus Tecfidera.

Name

Banner Life Sciences

Legal name

Banner Life Sciences LLC

Website

https://bannerls.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Banner Life Sciences is a U.S. specialty pharmaceutical company that develops and commercializes BAFIERTAM, an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, now operating as a subsidiary of UK-based Cycle Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Multiple Sclerosis Therapeutics)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Specialty pharmaceuticals
• Multiple sclerosis therapy
• Oral MS treatment
• Neurology drug development
• Delayed-release formulations

Headquarters

HQ city

High Point

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical product sales: Banner Life Sciences generates revenue through the sale of BAFIERTAM (monomethyl fumarate), a prescription disease-modifying therapy for relapsing forms of multiple sclerosis. BAFIERTAM was granted final FDA approval on April 30, 2020, enabling commercial sales in the U.S. market. The product competes as a bioequivalent alternative to Biogen's Tecfidera.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Banner Life Sciences combines formulation expertise with proprietary technologies to develop and commercialize specialty pharmaceuticals for patients with unmet clinical needs. Its flagship product, BAFIERTAM (monomethyl fumarate) delayed-release capsules, is an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) at a lower dose with potentially improved gastrointestinal tolerability. The product is dispensed through U.S. specialty and retail pharmacies and supported by the Cycle Vita patient support program.

Product overview

Banner Life Sciences is a specialty pharmaceutical company that develops and commercializes specialty pharmaceuticals for patients with unmet clinical needs. The company operates as a Cycle Pharmaceuticals company and its core product portfolio includes BAFIERTAM (monomethyl fumarate), an oral disease-modifying therapy for relapsing forms of multiple sclerosis. Patient support is delivered through Cycle Vita, which provides individualized support services for MS patients. Additionally, Cycle offers TASCENSO ODT (fingolimod) as another oral MS medication under the Cycle Vita support program.

Differentiator

Problem solved

Functional benefit

Brands

• BAFIERTAM®: Monomethyl fumarate delayed-release capsules - a disease-modifying therapy (DMT) for the treatment of relapsing forms of multiple sclerosis. Bioequivalent alternative to Biogen's Tecfidera®.

Products and services

• BAFIERTAM (monomethyl fumarate) delayed-release capsules An oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) that requires no dietary restrictions and no metabolic conversion.
• Cycle Vita Patient Support for BAFIERTAM Patient support program providing individualized financial, product, process, and clinical support to eligible patients starting BAFIERTAM therapy, including a dedicated MS support line and a team of Clinical Education Managers.

Quantifiable outcome

• Lower dose of BAFIERTAM is equivalent to Tecfidera and may improve gastrointestinal tolerability for patients, especially early in treatment.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core and minor.

• Cycle VitacoreGTM or Marketing Partner · 31 March 2025Cycle Vita expanded its patient support services in Multiple Sclerosis to include BAFIERTAM from April 1, 2025. Cycle Vita provides individualized financial, product, process and clinical support to eligible patients. New patients starting BAFIERTAM from April 2025 onwards are supported by Cycle Vita. Existing patients are being migrated from Banner Patient Support to Cycle Vita in partnership with their healthcare providers. Cycle Vita's MS-dedicated support services and team of Clinical Education Managers are now available to BAFIERTAM patients.
• Biogen Inc.minorOthers · 30 April 2020Biogen Inc. is the maker of Tecfidera (dimethyl fumarate), to which BAFIERTAM (monomethyl fumarate) is bioequivalent. Banner Life Sciences engaged in patent litigation with Biogen regarding U.S. Patent Number 7,619,001 ('the '001 patent'). The U.S. District Court for the District of Delaware ruled in favor of Banner in January 2019, and the U.S. Court of Appeals for the Federal Circuit upheld this decision on April 21, 2020, confirming BAFIERTAM does not infringe the '001 patent.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Sanofi: Markets Aubagio (teriflunomide), an oral DMT for relapsing MS. Sanofi is a direct competitor in the oral disease-modifying therapy category alongside BAFIERTAM.
• Novartis: Markets Gilenya (fingolimod), Kesimpta (ofatumumab), and Mayzent (siponimod) for MS — covering both oral and high-efficacy injectable options in the same relapsing MS patient population Banner targets.
• Biogen: Innovator of Tecfidera (dimethyl fumarate), the reference product to which BAFIERTAM is a bioequivalent. Biogen is the most direct competitor in the U.S. relapsing MS oral fumarate market and the party Banner litigated against in the '001 patent case.
• Merck KGaA: Markets Mavenclad (cladribine), an oral high-efficacy DMT for relapsing MS, placing Merck KGaA in direct competition with BAFIERTAM for oral RRMS prescriptions.
• Bristol Myers Squibb: Markets Zeposia (ozanimod), an oral S1P modulator approved for relapsing forms of MS. BMS competes head-to-head with BAFIERTAM for neurologist prescriptions in the oral DMT category.

Broad incumbents

• Roche: Markets Ocrevus (ocrelizumab), the leading high-efficacy anti-CD20 therapy for relapsing and primary progressive MS. Roche's commercial reach and clinical profile anchor the treatment paradigm Banner competes within.
• Viatris: Large generics and specialty manufacturer with broad MS-related product exposure, including authorized generic Tecfidera. Comparable as the kind of low-cost generic competitor that frames BAFIERTAM's commercial pricing pressure.
• Teva Pharmaceutical Industries: Markets Copaxone (glatiramer acetate), one of the legacy injectable DMTs in MS, and is a broad neurology/specialty pharma incumbent. Comparable as a long-standing specialty pharma player in the MS DMT market.

Emerging players

• TG Therapeutics: Smaller specialty pharma developing Briumvi (ublituximab) for relapsing MS. Comparable as an emerging competitor pursuing differentiated MS therapies against larger incumbents.
• Mapi Pharma: Israeli specialty pharma developing long-acting glatiramer acetate (GA Depot) for MS, with a 505(b)(2)-style reformulation approach. Comparable as a smaller specialty player pursuing differentiated, longer-acting formulations in the same indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Banner_LS

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Banner Life Sciences